Changes
/* Overview */
=Overview=
Glycogen synthase kinase-3 (GSK-3) has recently emerged, in the field of medicinal chemistry, as one of the most attractive therapeutic targets for the development of selective inhibitors as promising new drugs for numerous serious pathologies, including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer, alopecia and Type II diabetes. The full potential of GSK-3 inhibitors is yet to be realised and the number of drug candidates being developed by both academic centres and pharmaceutical companies has increased exponentially in the last three years. This review discloses recent discoveries on peptides and small molecules targeting GSK-3. Antisense therapy for the modulation of GSK-3 expression is also discussed. Focusing attention on this exciting target could thus reap considerable clinical and economic rewards.[http://www.expertopin.com/doi/abs/10.1517/13543776.16.6.773 source]
Prediction search done on NetPhos 2.0 server, which produces neural network predictions for serine, threonine and tyrosine phosphorylation sites in eukaryotic proteins.
[[image:predication-gsk3.jpg|center|300 800 px]] '''DISPHOS (Disorder-Enhanced Phosphorylation Sites Predictor) Results''' [[image:predication-gsk3-2.jpg|center|800 px]]
==Amino Acid Sequence==
[[image:gsk-3 sequence.jpg|center|800 px]]
== Ways to inhibit GSK3==
Possible ways in the art to inihibit GSK3 is illustrated in following figure:
[[image:ways to inhibit gsk3.jpg|center|500 px]]
=Beta-catenin=
==Structure==
Beta-catenin consists of 781 amino acid residue.
[[image:catenin.jpg|500 px|center]]
'''Amino Acid Sequence'''
1 MATQADLMEL DMAMEPDRKA AVSHWQQQSY LDSGIHSGAT TTAPSLSGKG NPEEEDVDTS <br>
61 QVLYEWEQGF SQSFTQEQVA DIDGQYAMTR AQRVRAAMFP ETLDEGMQIP STQFDAAHPT<br>
121 NVQRLAEPSQ MLKHAVVNLI NYQDDAELAT RAIPELTKLL NDEDQVVVNK AAVMVHQLSK<br>
181 KEASRHAIMR SPQMVSAIVR TMQNTNDVET ARCTAGTLHN LSHHREGLLA IFKSGGIPAL<br>
241 VKMLGSPVDS VLFYAITTLH NLLLHQEGAK MAVRLAGGLQ KMVALLNKTN VKFLAITTDC<br>
301 LQILAYGNQE SKLIILASGG PQALVNIMRT YTYEKLLWTT SRVLKVLSVC SSNKPAIVEA<br>
361 GGMQALGLHL TDPSQRLVQN CLWTLRNLSD AATKQEGMEG LLGTLVQLLG SDDINVVTCA<br>
421 AGILSNLTCN NYKNKMMVCQ VGGIEALVRT VLRAGDREDI TEPAICALRH LTSRHQEAEM<br>
481 AQNAVRLHYG LPVVVKLLHP PSHWPLIKAT VGLIRNLALC PANHAPLREQ GAIPRLVQLL<br>
541 VRAHQDTQRR TSMGGTQQQF VEGVRMEEIV EGCTGALHIL ARDVHNRIVI RGLNTIPLFV<br>
601 QLLYSPIENI QRVAAGVLCE LAQDKEAAEA IEAEGATAPL TELLHSRNEG VATYAAAVLF<br>
661 RMSEDKPQDY KKRLSVELTS SLFRTEPMAW NETADLGLDI GAQGEPLGYR QDDPSYRSFH<br>
721 SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD<br>
781 l
==Role of beta catenin==
* Stabilized β-catenin can induce new hair follicles and trichofolliculoma-like tumors in skin. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144#B33 source]
* Follicular (hair) and epidermal stem cells are located in the bulge region.
* In the absence of β-catenin, stem cells can differentiate into the epidermal lineage but not into the hair follicular lineage. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144 source]
* In a research, expression of stabilized β-catenin in the epidermis of transgenic mice resulted in hair follicle morphogenesis. [http://www.biomedcentral.com/1471-2121/7/4#B8 source]
[[image:in action.jpg|center|400 px]]
Anonymous user
